Frontotemporal disorder, commonly known as Pick disease, is a form of dementia which is caused by a family of brain disorders known as frontotemporal lobar degeneration (FTLD). Frontotemporal dementia is a rare type of dementia which causes behaviour and language problems. Dementia is associated with disorders of mental abilities caused by some changes and damage in the brain and affects the front and sides of the brain. Dementia mostly affects people aged over 65 years, but frontotemporal dementia tends to start at a younger age. The common cases are diagnosed in people aged between 45-65 years, although it can also affect younger or older people. The mutation of different genes, such as VCP, CHMP2B, Tau gene, PGRN gene, FUS genes, TARDBP, and C9ORF72 gene are likely to cause frontotemporal disorders. Some of the common symptoms of frontotemporal disorders include dysarthria, perseveration, aphasia, utilization behaviour, social disinhibition, emotional changes, social-interpersonal changes, apraxia, gait disorder, dystonia, among others.
The diagnosis of frontotemporal disorders is mainly made through genetic tests, blood test, and physical examinations. These tests help to understand similar conditions, genetic mutation tests, and brain imaging changes in temporal and frontal lobes. Antipsychotics and antidepressants and antipsychotics medications can help in curing the symptoms of frontotemporal disorders. With increasing clinical trials and investment support from giant pharmaceutical companies to develop a treatment for this disorder is expected to drive the market growth during the forecast period.
Market Dynamics
Drivers
- Rising prevalence of frontotemporal disorders
- Increasing Funding by Government & Non-Government Organizations
Restraints
- High cost of treatment
- Challenges associated with diagnosis and treatment
Rising prevalence of frontotemporal disorders
The increased awareness towards pathogenesis of frontotemporal dementia (FTD) and its treatment models has led to the growth of global frontotemporal disorders market.
Currently, there is no approved pharmacological medication for prevention or curative treatment of FTD and available treatment options are only for symptomatic relief. The knowledge on underlying genetic causes, molecular behavior and emotion disturbances led to physicians prescribing drugs such as antidepressants, cognitive enhancers, and antipsychotics. The FTD treatment market has been witnessing rapid growth with increasing diagnosis of the target disease. The rising incidence and prevalence of frontotemporal disorders is the primary factor for the growth of frontotemporal disorder treatment market
Also, the increasing diagnosis of dementia cases is likely to increase the prevalence of FTD, thereby driving the treatment market. According to World Health Organization (WHO), the prevalence of dementia reached 50 million in 2017 and the number of new cases at 10 million every year. Europe is experiencing the highest rate of new incidence with countries such as U.K., Finland, and Italy at top spots globally in terms of incidence rate. In England, FTD is estimated account for nearly 8% of the overall dementia population
Geographical Analysis
North America is growing at the CAGR of 7.0% during the forecast period (2020-2027).
North America dominated with revenue estimated as a result of the presence of sophisticated healthcare facilities and infrastructure in developed countries, such as the U.S. High purchasing power for expensive drugs, reimbursement policies and increasing patient pool are the drivers projected to boost the market demand. As per the National Institute of Neurological Disorders and Stroke, Alzheimer’s disease alone, as one dementia disorder, affects more than 5 million people in the U.S. The toll on individuals, caregivers and society is enormous and is expected to increase as the population ages. This aids in supplementing the regional growth. The toll on individuals, society, and caregivers is enormous and is expected to increase as the population ages. Frontotemporal dementia falls under rare diseases or orphan indications. In the United States, around 30,000 to 40,000 patients are suffering from frontotemporal disorders. Treatment of frontotemporal disorders falls under the Orphan Drug Act of 1983 as orphan drug indications are those which affect less than 200,000 people in the U.S.
Diagnosis of frontotemporal disorders can be confirmed through genetic tests, physical examinations, and blood tests. These tests help to understand similar conditions, genetic mutation tests, and brain imaging changes in temporal and frontal lobes. Generally, onset of this disorder occurs in the age range of 50 to 60 years, and affected 50,000 to 60,000 Americans in 2011. Currently, no treatments are available to cure or slow the progression of FTD, but healthcare providers may prescribe medicine to treat symptoms. Antidepressants may help treat anxiety and control obsessive-compulsive behaviors and other symptoms.
Although clinical trials have been produced in the USA, a number of interventions other than medication, a consistently high rate of clinical trial failure is cited as a significant factor influencing the prospects of frontotemporal disorders treatment in the forecast period. Moreover, there is a rise in the geriatric population in the United States, which is expected to create more opportunities for market players in the region. According to the Anxiety and Depression Association of America, Facts, and Statistics, anxiety disorder is one of the most common mental illnesses in the United States, affecting approximately 40 million American adults every year, which is 18.1% of the total population of the United States. Additionally, more than 16.1 million American adults suffer from major depressive disorder every year, and it is more prevalent in women than men. Thus, the increasing prevalence of frontotemporal disorders and increasing rate of consumption of antidepressants are expected to drive the market in the forecast period.
About Us:
DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year, we have secured more than 100 unique customers from established organizations all over the world.
For more information:
Sai Kiran
Sales Manager at DataM Intelligence
Email: [email protected]
Tel: +1 877 441 4866
Website: www.datamintelligence.com